AU2001283964A1 - Composition for combined use of aromatase inhibitors - Google Patents

Composition for combined use of aromatase inhibitors

Info

Publication number
AU2001283964A1
AU2001283964A1 AU2001283964A AU8396401A AU2001283964A1 AU 2001283964 A1 AU2001283964 A1 AU 2001283964A1 AU 2001283964 A AU2001283964 A AU 2001283964A AU 8396401 A AU8396401 A AU 8396401A AU 2001283964 A1 AU2001283964 A1 AU 2001283964A1
Authority
AU
Australia
Prior art keywords
composition
combined use
aromatase inhibitors
aromatase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001283964A
Inventor
Giorgio Massimini
Dinesh Purandare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn SpA
Pharmacia and Upjohn Co
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA, Pharmacia and Upjohn Co, Upjohn Co filed Critical Pharmacia and Upjohn SpA
Publication of AU2001283964A1 publication Critical patent/AU2001283964A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
AU2001283964A 2000-08-09 2001-07-27 Composition for combined use of aromatase inhibitors Abandoned AU2001283964A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63506500A 2000-08-09 2000-08-09
US09/635,065 2000-08-09
PCT/EP2001/008707 WO2002011705A2 (en) 2000-08-09 2001-07-27 Composition for combined use of aromatase inhibitors

Publications (1)

Publication Number Publication Date
AU2001283964A1 true AU2001283964A1 (en) 2002-02-18

Family

ID=24546291

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001283964A Abandoned AU2001283964A1 (en) 2000-08-09 2001-07-27 Composition for combined use of aromatase inhibitors

Country Status (5)

Country Link
US (1) US20030158168A1 (en)
EP (1) EP1322333A2 (en)
JP (1) JP2004505909A (en)
AU (1) AU2001283964A1 (en)
WO (1) WO2002011705A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
EP1737461B1 (en) * 2004-03-15 2012-12-12 PTC Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
AU2008239598A1 (en) * 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8517360D0 (en) * 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
DE19610645A1 (en) * 1996-03-06 1997-09-11 Schering Ag Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination for the manufacture of a medicament for the treatment of a relative and absolute androgen deficiency in men

Also Published As

Publication number Publication date
WO2002011705A2 (en) 2002-02-14
JP2004505909A (en) 2004-02-26
US20030158168A1 (en) 2003-08-21
WO2002011705A3 (en) 2002-11-21
EP1322333A2 (en) 2003-07-02

Similar Documents

Publication Publication Date Title
AU2002305205A1 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
HUP0202332A2 (en) Pyrazole compositions useful as inhibitors of erk
AU2001294515A1 (en) Use of stat-6 inhibitors as therapeutic agents
AU2001244399A1 (en) Gamma-secretase inhibitors
AU2002334969A1 (en) Use of stat-6 inhibitors as therapeutic agents
GB0025782D0 (en) Use of inhibitors
AU2001236720A1 (en) Compositions useful as inhibitors of erk
AU2002213485A1 (en) Inhibitors of protein kinases
AU7490900A (en) Chemical compounds and compositions and their use as cathepsin s inhibitors
AU2002214163A1 (en) Pyridyl-substituted triazoles as tgf inhibitors
HUP0300061A3 (en) Use of il-18 inhibitors
AP2003002719A0 (en) Use of cox-2 inhibitors for preventing immunodeficiency
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
AU9625501A (en) Substituted azole derivatives as inhibitors of corticotropin releasing factor
AU2002238103A1 (en) Use of beta-lactamase inhibitors as neuroprotectants
AU2002338734A1 (en) Use of phosphorodiesterase IV inhibitors
HUP0401641A3 (en) Use of substituted diazonine derivatives as phosphorodiesterase iv inhibitors
AU2002214038A1 (en) Inhibitors of transglutaminases
IL131047A0 (en) Use of il-18 inhibitors
AU2002222933A1 (en) Inhibitors of factor xa
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU2001283964A1 (en) Composition for combined use of aromatase inhibitors
AU2002364911A1 (en) Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use
IL158395A0 (en) Aromatase inhibitor for use in reproduction
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors